PCM
SUPN icon

Peregrine Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Peregrine Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-135,678
Closed -$4.91M – 338
2024
Q4 		$4.91M Sell
135,678
-63,974
-32% -$2.25M 0.15% 226
2024
Q3 		$6.23M Sell
199,652
-2,642
-1% -$82.5K 0.19% 163
2024
Q2 		$5.41M Sell
202,294
-699
-0.3% -$20.3K 0.16% 220
2024
Q1 		$6.92M Buy
+202,993
New +$6.04M 0.2% 174

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Peregrine Capital Management's SUPN Position: Q1 2025 in Review

Peregrine Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2025, closing a stake of 135,678 shares — an estimated $4.91M sold.

Peregrine Capital Management first reported a position in SUPN in Q1 2024 and held it in 4 quarters. The position peaked at $6.92M in Q1 2024. 295 funds tracked by Wall St. Rank hold SUPN as of Q1 2025.

  • Peregrine Capital Management reported no remaining Supernus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Peregrine Capital Management sold 135,678 Supernus Pharmaceuticals shares in Q1 2025, an estimated $4.91M.
  • Peregrine Capital Management first reported a position in Supernus Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Peregrine Capital Management's Supernus Pharmaceuticals position peaked at $6.92M in Q1 2024.
  • 295 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2025.

Based on Peregrine Capital Management's 13F filing for Q1 2025, filed 25 Apr 2025.